Phase I trial of vandetanib (ZD6474, ZACTIMA) with concurrent radiation in treatment of newly diagnosed brainstem glioma.

Trial Profile

Phase I trial of vandetanib (ZD6474, ZACTIMA) with concurrent radiation in treatment of newly diagnosed brainstem glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2012

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Oct 2011 Planned end date changed from 1 Jan 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Planned number of patients changed from 28 to 35 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top